Clinical Application of LCBP Risk Assessment Model in Risk Stratification of Pulmonary Nodules

Objective: To use the LCBP risk assessment model to evaluate tumor markers combined with imaging diagnosis, stratify the risk of pulmonary nodules, and predict the probability of disease malignancy in patients. Methods: A total of 80 patients with pulmonary nodules on lung CT examination in the Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine from January 2020 to April 2021 were enrolled as the experimental group, and 60 patients without pulmonary nodules were selected as the control group. Blood samples were collected from patients without treatment, and ProGRP, CEA, SCC-AG and CYFRA21-1 serum biomarkers were determined by chemiluminescence immunoassay. Results: There were statistically significant differences in serological markers between the two groups (P<0.05), and the evaluation of the malignant probability of pulmonary nodules by imaging indicators and the presence or absence of burr signs were statistically significant (P<0.05). The AUC of the low-risk group was 0.761, the AUC of the intermediate-risk group was 0.749, and the AUC of the high-risk group was 0.804. Conclusion: The LCBP risk assessment model based on serological markers, imaging findings and clinical data has a good ability to distinguish the risk stratification of pulmonary nodules